- Home
- STSS vs SCNI Comparison
STSS vs SCNI Comparison
Compare STSS & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- SCNI
- Stock Information
- Founded
- STSS 2017
- SCNI 2003
- Country
- STSS United States
- SCNI Israel
- Employees
- STSS N/A
- SCNI N/A
- Industry
- STSS Medical/Dental Instruments
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STSS Health Care
- SCNI Health Care
- Exchange
- STSS Nasdaq
- SCNI Nasdaq
- Market Cap
- STSS 3.3M
- SCNI 2.8M
- IPO Year
- STSS 2022
- SCNI N/A
- Fundamental
- Price
- STSS $0.37
- SCNI $3.33
- Analyst Decision
- STSS
- SCNI
- Analyst Count
- STSS 0
- SCNI 0
- Target Price
- STSS N/A
- SCNI N/A
- AVG Volume (30 Days)
- STSS 41.3M
- SCNI 5.1K
- Earning Date
- STSS 03-31-2025
- SCNI 11-22-2024
- Dividend Yield
- STSS N/A
- SCNI N/A
- EPS Growth
- STSS N/A
- SCNI N/A
- EPS
- STSS N/A
- SCNI 8.20
- Revenue
- STSS N/A
- SCNI $452,000.00
- Revenue This Year
- STSS N/A
- SCNI N/A
- Revenue Next Year
- STSS N/A
- SCNI N/A
- P/E Ratio
- STSS N/A
- SCNI $0.41
- Revenue Growth
- STSS N/A
- SCNI N/A
- 52 Week Low
- STSS $0.25
- SCNI $2.23
- 52 Week High
- STSS $18.15
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- STSS 42.15
- SCNI 46.19
- Support Level
- STSS $0.28
- SCNI $3.25
- Resistance Level
- STSS $0.70
- SCNI $3.48
- Average True Range (ATR)
- STSS 0.08
- SCNI 0.13
- MACD
- STSS 0.06
- SCNI -0.01
- Stochastic Oscillator
- STSS 26.32
- SCNI 29.03
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.